Effects of adjusting for censoring on meta-analyses of time-to-event outcomes

International Journal of Epidemiology

Volumn 31, Issue 1, 2002, Pages 107-111

  Vale, Claire L ^a   Tierney, Jayne F ^a   Stewart, Lesley A ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Censoring; Follow up; Meta analysis; Neoplasms; Randomized controlled trials; Survival analysis; Time to event

Indexed keywords

ANTINEOPLASTIC AGENT;

EPIDEMIOLOGY; META-ANALYSIS; METHODOLOGY;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LUNG CANCER; LUNG SURGERY; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; TIME; UTERINE CERVIX CANCER;

EID: 0036208148     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/31.1.107     Document Type: Article

References (9)

1. Censoring issues in survival analysis
2. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
3. Does neoadjuvant displatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: A meta-analysis of individual patient data from randomised clinical trials
4. Neoadjuvant and adjuvant chemotherapy
5. Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials
6. A meta-analysis using individual patient data from randomised clinical trials (RCTs) of adjuvant chemotherapy for soft-tissue tissue sarcomas (STS)
7. Treatment of Early Breast Cancer Vol. 1. Worldwide Evidence 1985-1990
8. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix?
9. Meta-analysis of the literature or of individual patient data: Is there a difference?